Napredna pretraga

Pregled bibliografske jedinice broj: 643763

Stable gastric pentadecapeptide BPC 157 for colitis and multiple sclerosis: Healing of cysteamine-colitis and colon-colon- anastomosis


Sikirić, Predrag; Kliček, Robert; Kolenc, Danijela; Šuran, Jelena; Drmić, Domagoj; Brčić, Luka; Aralica, Gorana; Seiwerth, Sven; Ručman, Rudolf
Stable gastric pentadecapeptide BPC 157 for colitis and multiple sclerosis: Healing of cysteamine-colitis and colon-colon- anastomosis // The FASEB Journal / Weissmann, Gerald (ur.).
Bethesda, USA: FASEB, 2013. str. 18-18 (predavanje, međunarodna recenzija, sažetak, znanstveni)


Naslov
Stable gastric pentadecapeptide BPC 157 for colitis and multiple sclerosis: Healing of cysteamine-colitis and colon-colon- anastomosis

Autori
Sikirić, Predrag ; Kliček, Robert ; Kolenc, Danijela ; Šuran, Jelena ; Drmić, Domagoj ; Brčić, Luka ; Aralica, Gorana ; Seiwerth, Sven ; Ručman, Rudolf

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
The FASEB Journal / Weissmann, Gerald - Bethesda, USA : FASEB, 2013, 18-18

Skup
Experimental Biology 2013

Mjesto i datum
Boston, USA, 20-24. 04. 2013

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
BPC 157; colitis; multiple sclerosis

Sažetak
BPC 157 is interesting as an original anti-ulcer peptide (GEPPPGKPADDAGLV, M.W. 1419) stable in human gastric juice more than 24 hours, successful in trials for inflammatory bowel disease, phase II, wound treatment, no toxicity or side effects reported, LD1 not achieved, effective alone without carrier. The dehiscence of colonic anastomosis is associated with high mortality and morbidity rates. As a result, the problem of healing after a colon resection requires a suitable solution, especially in inflammatory bowel disease with compromised healing. As a possible solution we suggest the use of BPC 157 which may also be effective for treating inflammatory bowel disease complications. After cysteamine (400 mg/kg ir) colon-colon anastomosis was created in rats. The sacrifice was at day 3, 5, 7, and 14. BPC 157 (10μg/kg, 10 ng/kg) was applied ip once daily or in drinking water (0.16 μg/ml/12ml/day) till the sacrifice. Controls poor presentation did not heal cysteamine colitis and colon-colon anastomosis ; BPC 157 simultaneously induced healing of both, the anastomosis and the ulcerative colitis. Thereby, this evidence advocates BPC 157 in inflammatory bowel disease. Interestingly, accordingly with application of agents used in ulcerative colitis (i.e., natalizumab), the most recent evidence suggests its use also in multiple sclerosis therapy.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Predrag Sikirić, )

Ustanove
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE